公开(公告)号：KR20180054427A

公开(公告)日：2018-05-24

申请号：KR20170126636

申请日：2017-09-28

Applicant: TOOLGEN INCORPORATED ,  SAMSUNG LIFE PUBLIC WELFARE FOUNDATION

Inventor： KIM SEOKJOONG ,  SONG DONG WOO ,  HONG YOUNG BIN ,  CHOI BYUNG OK ,  LEE JAE YOUNG ,  LEE JUNG MIN

IPC: C07K14/705 ,  A61K48/00 ,  C12N9/22 ,  C12N15/10 ,  C12N15/113 ,  C12N15/86

CPC classification number: C12N15/86 ,  C12N15/113 ,  C12N2310/20

Abstract: 본발명은 SC 기능조절및/또는 SC 기능장애로인한질환치료또는개선을위한, 인위적으로조작된 SC 기능조절인자및 이의이용에관한것이다. 보다구체적으로, SC 기능조절및/또는 SC 기능장애로인한질환치료또는개선을위한인위적으로조작된 SC 기능조절인자및/또는 SC 기능조절인자를인위적으로조작할수 있는조성물을포함하는, 인위적으로 SC 기능조절및/또는 SC 기능장애로인한질환치료또는개선할수 있는시스템에관한것이다. 구체적인양태로, 인위적으로조작된 PMP22 등의 SC 기능조절인자및/또는이의발현산물에의한 SC 기능조절시스템에관한것이다.

公开(公告)号：KR20180020929A

公开(公告)日：2018-02-28

申请号：KR20170105303

申请日：2017-08-21

Applicant: TOOLGEN INCORPORATED ,  SEOUL NATIONAL UNIV HOSPITAL ,  SEOUL NATIONAL UNIV R&DB FOUNDATION

Inventor： KIM JEONG HUN ,  PARK SUNG WOOK ,  KIM SEOK JOONG ,  SONG DONG WOO

IPC: C12N15/86 ,  A61K48/00 ,  C07K14/47 ,  C07K14/475 ,  C07K14/515 ,  C12N9/22 ,  C12N15/10 ,  C12N15/113 ,  C12N15/90

CPC classification number: A61K48/00 ,  C07K14/47 ,  C07K14/475 ,  C07K14/515 ,  C12N9/22 ,  C12N15/10 ,  C12N15/113 ,  C12N15/86 ,  C12N15/90

Abstract: 본발명은신생혈관형성조절을위한, 인위적으로조작된신생혈관형성관련인자및 이의이용에관한것이다. 보다구체적으로, 신생혈관형성을조절하기위한인위적으로조작된신생혈관형성관련인자및/또는신생혈관형성관련인자를인위적으로조작할수 있는조성물을포함하는, 인위적으로신생혈관형성을조절할수 있는시스템에관한것이다. 구체적인양태로, 인위적으로조작된 VEGFA, HIF1A, ANGPT2, EPAS1, ANGPTL4 등의신생혈관형성관련인자및/또는이의발현산물에의한신생혈관형성조절시스템에관한것이다.

Abstract translation: 本发明涉及人工改造的血管生成相关因子及其用于血管生成调节的用途。 更具体地说，本发明涉及可以人工调节血管生成的系统，包括人工改造的血管生成相关因子以调节血管生成和/或能够人工改造血管生成相关因子的组合物。 在具体方面，本发明涉及通过其表达产物人工改造的血管发生相关因子，例如VEGFA，HIF1A，ANGPT2，EPAS1，ANGPTL4等和/或血管生成调节系统。

公开(公告)号：AU2017358122B2

公开(公告)日：2022-12-22

申请号：AU2017358122

申请日：2017-09-28

Applicant: TOOLGEN INCORPORATED

Inventor： KIM SEOKJOONG ,  SONG DONG WOO ,  HONG YOUNG BIN ,  CHOI BYUNG OK ,  LEE JAE YOUNG ,  LEE JUNG MIN

IPC: C12N15/113 ,  A61K48/00 ,  C07K14/705 ,  C12N9/22 ,  C12N15/10 ,  C12N15/86

Abstract: The present invention relates to an artificially engineered SC function control factor for SC function control and/or the treatment or alleviation of a disease due to SC function disorder, and to a use thereof. More specifically, the present invention relates to a system capable of performing artificial SC function control and/or treating or alleviating a disease due to SC function disorder, the system comprising: an artificially engineered SC function control factor for SC function control and/or the treatment or alleviation of a disease due to SC function disorder; and/or a composition capable of artificially engineering an SC function control factor. In a specific aspect, the present invention relates to an SC function control system by an SC function control factor, such as artificially engineered PMP22, and/or an expression product thereof.

公开(公告)号：AU2017313616B2

公开(公告)日：2022-12-08

申请号：AU2017313616

申请日：2017-08-21

Applicant: INST FOR BASIC SCIENCE ,  SEOUL NATIONAL UNIV HOSPITAL ,  SEOUL NATIONAL UNIV R&DB FOUNDATION ,  TOOLGEN INCORPORATED

Inventor： KIM JEONG HUN ,  PARK SUNG WOOK ,  KIM SEOKJOONG ,  SONG DONG WOO

IPC: C12N15/12 ,  A61K48/00 ,  C07K14/47 ,  C07K14/475 ,  C07K14/515 ,  C12N9/22 ,  C12N15/10 ,  C12N15/113 ,  C12N15/86 ,  C12N15/90

Abstract: The present invention relates to artificially engineered angiogenesis-related factors and a use thereof, for angiogenesis regulation. More specifically, the present invention relates to a system that can artificially regulate angiogenesis, including artificially engineered angiogenesis-related factors to regulate angiogenesis and/or a composition capable of artificially engineering angiogenesis-related factors. In specific aspects, the present invention relates to artificially engineered angiogenesis-related factors such as VEGFA, HIF1A, ANGPT2, EPAS1, ANGPTL4, etc. and/or an angiogenesis regulatory system by their expression products thereof.